Superworth

COMPASS Pathways free cash flow CMPS

Cash from operations less capital spending, by quarter and over the last twelve months, from 2021.

Last 12 months, to Dec 31, 2024
−$119.2M
Latest quarter, Q4 FY24
−$41.8M
Fiscal year 2024
−$119.2M

COMPASS Pathways' free cash flow was −$119.2M over the twelve months to Dec 31, 2024.

In its latest quarter, Q4 FY24, it was −$41.8M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2024−$119.2Mn/a
FY2023−$97.4Mn/a
FY2022−$106Mn/a
FY2021−$68.1Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY24−$41.8Mn/a−$119.2M
Q3 FY24−$22.2Mn/a−$105.2M
Q2 FY24−$34.4Mn/a−$100.1M
Q1 FY24−$20.8Mn/a−$90.5M
Q4 FY23−$27.8Mn/a−$97.4M
Q3 FY23−$17.1Mn/a−$115.1M
Q2 FY23−$24.8Mn/a−$117M
Q1 FY23−$27.8Mn/a−$110.6M
Q4 FY22−$45.4Mn/a−$106M
Q3 FY22−$19Mn/a−$83.1M
Q2 FY22−$18.4Mn/a−$78.1M
Q1 FY22−$23.2Mn/a−$77.4M

Against its peers

Companies in Drug Manufacturers - General nearest COMPASS Pathways' size, closest first, today.

CompanyFree cash flow yield
CMPSCOMPASS Pathwaysn/m
PAHCPhibro Animal Health0.6%
ANABAnaptysbion/m
PCRXPacira BioSciences12.4%
ANIPANI Pharmaceuticals10.4%
OMEROmeros−5.7%
HRMYHarmony Biosciencesn/m
AMPHAmphastar Pharmaceuticals14.3%
PBHPrestige Consumer Healthcare10.4%
NRIXNurix Therapeutics13.4%
ABUSArbutus Biopharman/m
Peer median10.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on COMPASS Pathways

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.